- Home
- QS vs RYTM Comparison
QS vs RYTM Comparison
Compare QS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QS | RYTM |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | QS | RYTM |
|---|---|---|
| Price | $11.06 | $112.59 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $9.06 | ★ $125.77 |
| AVG Volume (30 Days) | ★ 17.9M | 887.7K |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $174,334,000.00 |
| Revenue This Year | N/A | $47.34 |
| Revenue Next Year | N/A | $57.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 54.92 |
| 52 Week Low | $3.40 | $45.91 |
| 52 Week High | $19.07 | $122.20 |
Technical Indicators
Market Signals| Indicator | QS | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 36.75 | 58.46 |
| Support Level | $11.57 | $109.59 |
| Resistance Level | $12.85 | $122.20 |
| Average True Range (ATR) | 0.66 | 5.23 |
| MACD | -0.00 | 1.09 |
| Stochastic Oscillator | 8.51 | 57.40 |
Price Performance
Historical ComparisonAbout QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.